Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Deals

Ronovo Surgical Secures Pre-Series B+ Funding to Advance Modular Surgical Robots

Fineline Cube Aug 30, 2023

Shanghai-based minimally invasive surgical robot developer, Ronovo Surgical, has reportedly raised close to RMB 200...

Company Drug

AIM Vaccine Co., Ltd Launches Phase III Trial for 23-Valent Pneumococcal Vaccine

Fineline Cube Aug 30, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the commencement of a Phase III...

Company Deals

Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies

Fineline Cube Aug 30, 2023

Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million)...

Company Deals

Epigenic Therapeutics Secures $32 Million in Series A Funding for Gene Modulation Therapy

Fineline Cube Aug 30, 2023

Epigenic Therapeutics, a Shanghai-based biotech company specializing in gene modulation therapy through epigenome regulation, has...

Company Deals

Biocytogen Pharmaceuticals’ Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies

Fineline Cube Aug 30, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd’s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced...

Company Drug

CSPC Pharmaceutical’s Biosimilar Ozempic Equivalent Gets NMPA Clinical Trial Approval

Fineline Cube Aug 30, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its biosimilar version of Novo...

Company Drug

Jiangsu Yahong Meditech Gets NMPA Approval for APL1401 Ulcerative Colitis Trial

Fineline Cube Aug 30, 2023

Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer based in...

Company

Luye Pharma Group Reports H1 2023 Revenue Growth with Strong Oncology and CNS Sales

Fineline Cube Aug 30, 2023

China-based Luye Pharma Group (HKG: 2186) has announced its financial performance for the first half...

Company

Fosun Pharma Reports Moderate Revenue Growth and Increased R&D Spend in 2023 Interim Report

Fineline Cube Aug 30, 2023

Fosun Pharma (SHA: 600196) has released its 2023 interim financial report, recording revenues of RMB...

Company Drug

Roche’s Evrysdi Receives EC Approval for Expanded Indication in Infants with SMA

Fineline Cube Aug 30, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has received regulatory approval from the European Commission (EC)...

Company Drug

MSD’s Keytruda Gains EC Approval for First-Line HER2-Positive Gastric Cancer Treatment

Fineline Cube Aug 30, 2023

The European Commission (EC) has granted an additional indication to Merck, Sharp & Dohme (MSD;...

Company Drug

BMS’ Reblozyl Expands Indication to Include First-Line MDS-Related Anemia Treatment

Fineline Cube Aug 30, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has received an indication extension approval from the US Food...

Company Policy / Regulatory

HHS Releases List of 10 Drugs for Medicare Price Negotiations Starting 2026

Fineline Cube Aug 30, 2023

The Department of Health and Human Services (HHS) in the US has released a list...

Company Drug

ImmunoTech Biopharm’s EAL Earns Breakthrough Therapy Designation for HCC Recurrence Prevention

Fineline Cube Aug 29, 2023

The Center for Drug Evaluation (CDE) in China has indicated on its website that Immunotech...

Company Deals

Mabwell Bioscience Secures Deal with UNILAB for Biosimilar Humira in the Philippines

Fineline Cube Aug 29, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing and supply agreement...

Company Deals

HanchorBio and Henlius Pharmaceutical Enter Strategic Collaboration for Immunotherapies

Fineline Cube Aug 29, 2023

Taiwan-based HanchorBio has entered into a strategic cooperation framework agreement with Shanghai-headquartered Shanghai Henlius Biotech,...

Company Medical Device

Novocure’s TTFields Misses Overall Survival Endpoint in Ovarian Cancer Phase III Trial

Fineline Cube Aug 29, 2023

Switzerland-based Novocure (NASDAQ: NVCR) has experienced a setback with its Tumor Treating Fields (TTFields) product,...

Company Drug

Harbour BioMed’s HBM9033 ADC Receives US FDA IND Clearance for Clinical Trials

Fineline Cube Aug 29, 2023

China-based Harbour BioMed (HKG: 2142) has announced receiving Investigational New Drug (IND) clearance from the...

Company Deals

Sandoz Expands Anti-Infective Portfolio with Acquisition of Astellas Pharma’s Antifungal Mycamine

Fineline Cube Aug 29, 2023

Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz has bolstered its global anti-infectives portfolio with the acquisition...

Company Deals

BMS Partners with Cellares for Automated CAR-T Cell Therapy Production

Fineline Cube Aug 29, 2023

Pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with cell therapy...

Posts pagination

1 … 524 525 526 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.